Holen Sie sich die Stockscreener-App
7.58
10.50%
0.72
Handel nachbörslich:
7.60
0.02
+0.26%
Schlusskurs vom Vortag:
$6.86
Offen:
$6.89
24-Stunden-Volumen:
219.59K
Relative Volume:
1.36
Marktkapitalisierung:
$162.03M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-1.5313
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
+6.46%
1M Leistung:
+15.55%
6M Leistung:
+1.07%
1J Leistung:
-39.89%
1-Tages-Spanne:
$6.6001
$7.63
1-Wochen-Bereich:
$6.45
$7.73
52-Wochen-Spanne:
$4.09
$13.43
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
7.58 | 146.64M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsJuly 2025 Opening Moves & Fast Moving Trade Plans - Newser
Does Enanta Pharmaceuticals Inc. qualify in momentum factor screeningTrade Volume Report & Weekly Market Pulse Updates - Newser
What MACD and RSI say about Enanta Pharmaceuticals Inc.Gold Moves & Fast Entry Momentum Trade Alerts - Newser
Will Enanta Pharmaceuticals Inc. continue its uptrendMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Has Enanta Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility Review2025 Fundamental Recap & Daily Volume Surge Trade Alerts - Newser
How high can Enanta Pharmaceuticals Inc. stock go2025 Price Action Summary & High Conviction Investment Ideas - Newser
JMP Securities Issues Positive Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World
Citizens JMP raises Enanta Pharmaceuticals stock price target to $25 from $24 - Investing.com Canada
Order flow analysis tools used on Enanta Pharmaceuticals Inc.Daily Profit Watch With Forecast Confidence - Newser
Top chart patterns to watch in Enanta Pharmaceuticals Inc.Free Capital Growth With Controlled Risk Picks - Newser
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - BioSpace
Enanta Pharmaceuticals Reports Steady Progress in Q3 2025 - TipRanks
What makes Enanta Pharmaceuticals Inc. stock price move sharplyFree Entry Plan for Oversold Reversal Stocks - Newser
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
Enanta Pharmaceuticals Sees Narrower Losses And Brighter Analyst Views - Finimize
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - San Francisco Chronicle
Enanta Pharmaceuticals shares rise 1.85% after-hours following positive RSVHR trial progress and FDA label expansion approval. - AInvest
Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Enanta Q3 FY22 Revenue Down 17% YoY, Operations Supported by $204.1mln. - AInvest
Detecting price anomalies in Enanta Pharmaceuticals Inc. with AIEquity Portfolio Outlook and Performance Summary - Newser
Leading vs lagging indicators on Enanta Pharmaceuticals Inc. performanceFree Daily Profit Focused Stock Screener - Newser
Will Enanta Pharmaceuticals Inc. price bounce be sustainableRisk-Managed Swing Setup and Signal Analysis - Newser
What technical models suggest about Enanta Pharmaceuticals Inc.’s comebackProfitable Trading Blueprint with Entry Zones - Newser
Is it too late to sell Enanta Pharmaceuticals Inc.Weekly Trend Watch with Market Signals - Newser
How Interest Rate Changes Impact Enanta Pharmaceuticals Inc. Stock PerformanceSummary of Reliable Long-Term Trade Models - Newser
Enanta Pharmaceuticals Inc. recovery potential after sell offSafe Entry Screening with Data Backed Analysis - Newser
Enanta ENTA 2025Q3 Earnings Preview Downside Ahead on Weak Revenue Projections - AInvest
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration - Seeking Alpha
Enanta Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveFree Trade Setups With Clear Risk Limits - Newser
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - BioSpace
Enanta Pharmaceuticals to Participate in H.C. Wainwright & Co.'s Virtual Fireside Chat - AInvest
Can volume confirm reversal in Enanta Pharmaceuticals Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):